World Health Organisation. World Malaria Report 2023. WHO Press (2023).
Josling, G. A., Williamson, K. C. & Llinas, M. Regulation of sexual commitment and gametocytogenesis in malaria parasites. Annu Rev. Microbiol 72, 501–519 (2018).
Venugopal, K., Hentzschel, F., Valkiunas, G. & Marti, M. Plasmodium asexual growth and sexual development in the haematopoietic niche of the host. Nat. Rev. Microbiol 18, 177–189 (2020).
Rabinovich, R. N. et al. malERA: An updated research agenda for malaria elimination and eradication. PLoS Med 14, e1002456 (2017).
Dhorda, M., Amaratunga, C. & Dondor,p A. M. Artemisinin and multidrug-resistant Plasmodium falciparum – a threat for malaria control and elimination. Curr. Opin. Infect. Dis. 34, 10.1097/QCO.0000000000000766 (2021).
Plouffe, D. M. et al. High-throughput assay and discovery of small molecules that interrupt malaria transmission. Cell Host Microbe 19, 114–126 (2016).
Birkholtz, L. M., Alano, P. & Leroy, D. Transmission-blocking drugs for malaria elimination. Trends Parasitol. 38, 390–403 (2022).
Burrows, J. N. et al. New developments in anti-malarial target candidate and product profiles. Malar. J. 16, 26 (2017).
Adjalley, S. H. et al. Quantitative assessment of Plasmodium falciparum sexual development reveals potent transmission-blocking activity by methylene blue. Proc. Natl Acad. Sci. USA 108, E1214–E1223 (2011).
Reader, J., van der Watt, M. E. & Birkholtz, L. M. Streamlined and Robust Stage-Specific Profiling of Gametocytocidal Compounds Against Plasmodium falciparum. Front Cell Infect. Microbiol 12, 926460 (2022).
Bousema, T. et al. Revisiting the circulation time of Plasmodium falciparum gametocytes: molecular detection methods to estimate the duration of gametocyte carriage and the effect of gametocytocidal drugs. Malar. J. 9, 136 (2010).
Stone, W. et al. Pyronaridine-artesunate or dihydroartemisinin-piperaquine combined with single low-dose primaquine to prevent Plasmodium falciparum malaria transmission in Ouélessébougou, Mali: a four-arm, single-blind, phase 2/3, randomised trial. Lancet Microbe 3, e41–e51 (2022).
Vanheer, L. N. et al. The transmission blocking activity of artemisinin-combination, non-artemisinin, and 8-aminoquinoline antimalarial therapies: a pooled analysis of individual participant data. medRxiv, 2024.2009.2027.24314479 (2024).
White, N. J. Primaquine to prevent transmission of falciparum malaria. Lancet Infect. Dis. 13, 175–181 (2013).
Butterworth, A. S., Skinner-Adams, T. S., Gardiner, D. L. & Trenholme, K. R. Plasmodium falciparum gametocytes: with a view to a kill. Parasitology 140, 1718–1734 (2013).
WHO Malaria Policy Advisory Committee and Secretariat. Malaria Policy Advisory Committee to the WHO: conclusions and recommendations of September 2012 meeting. Malar. J. 11, 424 (2012).
Stepniewska, K. et al. Efficacy of single-dose primaquine with artemisinin combination therapy on plasmodium falciparum gametocytes and transmission: an individual patient meta-analysis. J. Infect. Dis. 225, 1215–1226 (2022).
Mwaiswelo, R. O. et al. A single low dose of primaquine is safe and sufficient to reduce transmission of Plasmodium falciparum gametocytes regardless of cytochrome P450 2D6 enzyme activity in Bagamoyo district, Tanzania. Malar. J. 21, 84 (2022).
Dicko, A. et al. Efficacy and safety of primaquine and methylene blue for prevention of Plasmodium falciparum transmission in Mali: a phase 2, single-blind, randomised controlled trial. Lancet Infect. Dis. 18, 627–639 (2018).
Bastiaens, G. J. H. et al. Safety of single low-dose primaquine in glucose-6-phosphate dehydrogenase deficient falciparum-infected African males: Two open-label, randomized, safety trials. PLoS ONE 13, e0190272 (2018).
Goncalves, B. P. et al. Single low dose primaquine to reduce gametocyte carriage and Plasmodium falciparum transmission after artemether-lumefantrine in children with asymptomatic infection: a randomised, double-blind, placebo-controlled trial. BMC Med 14, 40 (2016).
Mahamar, A. et al. Artemether-lumefantrine with or without single-dose primaquine and sulfadoxine-pyrimethamine plus amodiaquine with or without single-dose tafenoquine to reduce Plasmodium falciparum transmission: a phase 2, single-blind, randomised clinical trial in Ouelessebougou, Mali. Lancet Microbe 5, 633–644 (2024).
Balikagala, B. et al. Evidence of Artemisinin-Resistant Malaria in Africa. N. Engl. J. Med 385, 1163–1171 (2021).
Rosenthal, P. J. et al. The emergence of artemisinin partial resistance in Africa: how do we respond? Lancet Infect. Dis. 24, e591–e600 (2024).
Phyo, A. P. et al. Emergence of artemisinin-resistant malaria on the western border of Thailand: a longitudinal study. Lancet 379, 1960–1966 (2012).
Witmer, K. et al. Transmission of artemisinin-resistant malaria parasites to mosquitoes under antimalarial drug pressure. Antimicrob Agents Chemother 65, 10.1128/AAC.00898-20 (2020).
Ngotho, P. et al. Revisiting gametocyte biology in malaria parasites. FEMS Microbiol Rev. 43, 401–414 (2019).
Delves, M. J. et al. Routine in vitro culture of P. falciparum gametocytes to evaluate novel transmission-blocking interventions. Nat. Protoc. 11, 1668–1680 (2016).
Ifediba, T. & Vanderberg, J. P. Complete in vitro maturation of Plasmodium falciparum gametocytes. Nature 294, 364–366 (1981).
Carter, R. & Miller, L. H. Evidence for environmental modulation of gametocytogenesis in Plasmodium falciparum in continuous culture. Bull. World Health Organ 57, 37–52 (1979).
Williams, J. L. Stimulation of Plasmodium falciparum gametocytogenesis by conditioned medium from parasite cultures. Am. J. Trop. Med Hyg. 60, 7–13 (1999).
Ponnudurai, T., Lensen, A. H., Meis, J. F. & Meuwissen, J. H. Synchronization of Plasmodium falciparum gametocytes using an automated suspension culture system. Parasitology 93, 263–274 (1986).
Fivelman, Q. L. et al. Improved synchronous production of Plasmodium falciparum gametocytes in vitro. Mol. Biochem Parasitol. 154, 119–123 (2007).
Brancucci, N. M., Goldowitz, I., Buchholz, K., Werling, K. & Marti, M. An assay to probe Plasmodium falciparum growth, transmission stage formation and early gametocyte development. Nat. Protoc. 10, 1131–1142 (2015).
Lelièvre, J. et al. Activity of clinically relevant antimalarial drugs on Plasmodium falciparum mature gametocytes in an ATP bioluminescence “transmission blocking” assay. PLoS One 7, e35019 (2012).
Miguel-Blanco, C. et al. Imaging-based high-throughput screening assay to identify new molecules with transmission-blocking potential against Plasmodium falciparum female gamete formation. Antimicrob. Agents Chemother. 59, 3298–3305 (2015).
Tanaka, T. Q. et al. A quantitative high throughput assay for identifying gametocytocidal compounds. Mol. Biochem Parasitol. 188, 20–25 (2013).
Sanders, N. G., Sullivan, D. J., Mlambo, G., Dimopoulos, G. & Tripathi, A. K. Gametocytocidal screen identifies novel chemical classes with Plasmodium falciparum transmission blocking activity. PLoS One 9, e105817 (2014).
Lucantoni, L. et al. A simple and predictive phenotypic High Content Imaging assay for Plasmodium falciparum mature gametocytes to identify malaria transmission blocking compounds. Sci. Rep. 5, 16414 (2015).
Lucantoni, L., Duffy, S., Adjalley, S. H., Fidock, D. A. & Avery, V. M. Identification of MMV malaria box inhibitors of plasmodium falciparum early-stage gametocytes using a luciferase-based high-throughput assay. Antimicrob. Agents Chemother. 57, 6050–6062 (2013).
Tanaka, T. Q. & Williamson, K. C. A malaria gametocytocidal assay using oxidoreduction indicator, alamarBlue. Mol. Biochem Parasitol. 177, 160–163 (2011).
Almela, M. J. et al. A new set of chemical starting points with plasmodium falciparum transmission-blocking potential for antimalarial drug discovery. PLoS One 10, e0135139 (2015).
Peatey, C. L., Leroy, D., Gardiner, D. L. & Trenholme, K. R. Anti-malarial drugs: how effective are they against Plasmodium falciparum gametocytes? Malar. J. 11, 34 (2012).
Peatey, C. L., Spicer, T. P., Hodder, P. S., Trenholme, K. R. & Gardiner, D. L. A high-throughput assay for the identification of drugs against late-stage Plasmodium falciparum gametocytes. Mol. Biochem Parasitol. 180, 127–131 (2011).
Reader, J. et al. Nowhere to hide: interrogating different metabolic parameters of Plasmodium falciparum gametocytes in a transmission blocking drug discovery pipeline towards malaria elimination. Malar. J. 14, 213 (2015).
Reader, J. et al. Multistage and transmission-blocking targeted antimalarials discovered from the open-source MMV Pandemic Response Box. Nat. Commun. 12, 269 (2021).
Sun, W. et al. Novel lead structures with both Plasmodium falciparum gametocytocidal and asexual blood stage activity identified from high throughput compound screening. Malar. J. 16, 147 (2017).
D’Alessandro, S. et al. A Plasmodium falciparum screening assay for anti-gametocyte drugs based on parasite lactate dehydrogenase detection. J. Antimicrob. Chemother. 68, 2048–2058 (2013).
Bolscher, J. M. et al. A combination of new screening assays for prioritization of transmission-blocking antimalarials reveals distinct dynamics of marketed and experimental drugs. J. Antimicrob. Chemother. 70, 1357–1366 (2015).
Duffy, S. & Avery, V. M. Identification of inhibitors of Plasmodium falciparum gametocyte development. Malar. J. 12, 408 (2013).
Abraham, M. et al. Probing the open global health chemical diversity library for multistage-active starting points for next-generation antimalarials. ACS Infect. Dis. 6, 613–628 (2020).
Paonessa, G. et al. Gametocyte-specific and all-blood-stage transmission-blocking chemotypes discovered from high throughput screening on Plasmodium falciparum gametocytes. Commun. Biol. 5, 547 (2022).
Lucantoni, L., Fidock, D. A. & Avery, V. M. Luciferase-based, high-throughput assay for screening and profiling transmission-blocking compounds against Plasmodium falciparum Gametocytes. Antimicrob. Agents Chemother. 60, 2097–2107 (2016).
D’Alessandro, S. et al. A chemical susceptibility profile of the Plasmodium falciparum transmission stages by complementary cell-based gametocyte assays. J. Antimicrob. Chemother. 71, 1148–1158 (2016).
Marin-Mogollon, C. et al. A P. falciparum NF54 Reporter Line Expressing mCherry-Luciferase in Gametocytes, Sporozoites, and Liver-Stages. Front Cell Infect. Microbiol 9, 96 (2019).
Miyazaki, Y. et al. A versatile Plasmodium falciparum reporter line expressing NanoLuc enables highly sensitive multi-stage drug assays. Commun. Biol. 6, 713 (2023).
Vaughan, A. M. et al. A transgenic Plasmodium falciparum NF54 strain that expresses GFP-luciferase throughout the parasite life cycle. Mol. Biochem Parasitol. 186, 143–147 (2012).
Delves, M. J. et al. Male and female Plasmodium falciparum mature gametocytes show different responses to antimalarial drugs. Antimicrob. Agents Chemother. 57, 3268–3274 (2013).
Ruecker, A. et al. A male and female gametocyte functional viability assay to identify biologically relevant malaria transmission-blocking drugs. Antimicrob. Agents Chemother. 58, 7292–7302 (2014).
Ponnudurai, T. et al. Infectivity of cultured Plasmodium falciparum gametocytes to mosquitoes. Parasitology 98, 165–173 (1989).
Stone, W. J. et al. A scalable assessment of Plasmodium falciparum transmission in the standard membrane-feeding assay, using transgenic parasites expressing green fluorescent protein-luciferase. J. Infect. Dis. 210, 1456–1463 (2014).
Spangenberg, T. et al. The open access malaria box: a drug discovery catalyst for neglected diseases. PLoS One 8, e62906 (2013).
Sun, W. et al. Chemical signatures and new drug targets for gametocytocidal drug development. Sci. Rep. 4, 3743 (2014).
Bowman, J. D. et al. Antiapicoplast and gametocytocidal screening to identify the mechanisms of action of compounds within the malaria box. Antimicrob. Agents Chemother. 58, 811–819 (2014).
Vos, M. W. et al. A semi-automated luminescence based standard membrane feeding assay identifies novel small molecules that inhibit transmission of malaria parasites by mosquitoes. Sci. Rep. 5, 18704 (2015).
Miguel-Blanco, C. et al. Hundreds of dual-stage antimalarial molecules discovered by a functional gametocyte screen. Nat. Commun. 8, 15160 (2017).
Vanheer L. N., Zhang H., Lin G., Kafsack B. F. C. Activity of Epigenetic Inhibitors against Plasmodium falciparum Asexual and Sexual Blood Stages. Antimicrob Agents Chemother 64, 10.1128/AAC.02523-19 (2020).
Coetzee, N. et al. Epigenetic inhibitors target multiple stages of Plasmodium falciparum parasites. Sci. Rep. 10, 2355 (2020).
Delves, M. J. et al. A high throughput screen for next-generation leads targeting malaria parasite transmission. Nat. Commun. 9, 3805 (2018).
Spicer, T. P. et al. Identification of Antimalarial Inhibitors Using Late-Stage Gametocytes in a Phenotypic Live/Dead Assay. SLAS Discov. 24, 38–46 (2019).
Boltryk, S. D. et al. CRISPR/Cas9-engineered inducible gametocyte producer lines as a valuable tool for Plasmodium falciparum malaria transmission research. Nat. Commun. 12, 4806 (2021).
Filarsky, M. et al. GDV1 induces sexual commitment of malaria parasites by antagonizing HP1-dependent gene silencing. Science 359, 1259–1263 (2018).
Nkrumah, L. J. et al. Efficient site-specific integration in Plasmodium falciparum chromosomes mediated by mycobacteriophage Bxb1 integrase. Nat. Methods 3, 615–621 (2006).
Prommana, P. et al. Inducible knockdown of Plasmodium gene expression using the glmS ribozyme. PLoS ONE 8, e73783 (2013).
Armstrong, C. M. & Goldberg, D. E. An FKBP destabilization domain modulates protein levels in Plasmodium falciparum. Nat. Methods 4, 1007–1009 (2007).
Branchini, B. R. et al. Red-emitting luciferases for bioluminescence reporter and imaging applications. Anal. Biochem 396, 290–297 (2010).
Siciliano, G. et al. A high susceptibility to redox imbalance of the transmissible stages of Plasmodium falciparum revealed with a luciferase-based mature gametocyte assay. Mol. Microbiol 104, 306–318 (2017).
Rice, B. W., Cable, M. D. & Nelson, M. B. In vivo imaging of light-emitting probes. J. Biomed. Opt. 6, 432–440 (2001).
Endo, M. & Ozawa, T. Advanced bioluminescence system for in vivo imaging with brighter and red-shifted light emission. Int. J. Mol. Sci. 21, 6538 (2020).
Lewis, M. D. et al. Bioluminescence imaging of chronic Trypanosoma cruzi infections reveals tissue-specific parasite dynamics and heart disease in the absence of locally persistent infection. Cell Microbiol 16, 1285–1300 (2014).
McLatchie, A. P. et al. Highly sensitive in vivo imaging of Trypanosoma brucei expressing “red-shifted” luciferase. PLoS Negl. Trop. Dis. 7, e2571 (2013).
Straimer, J. et al. Site-specific genome editing in Plasmodium falciparum using engineered zinc-finger nucleases. Nat. Methods 9, 993–998 (2012).
Szymczak, A. L. et al. Correction of multi-gene deficiency in vivo using a single ‘self-cleaving’ 2A peptide-based retroviral vector. Nat. Biotechnol. 22, 589–594 (2004).
Alano, P. et al. COS cell expression cloning of Pfg377, a Plasmodium falciparum gametocyte antigen associated with osmiophilic bodies. Mol. Biochem Parasitol. 74, 143–156 (1995).
Zhang, J. H., Chung, T. D. & Oldenburg, K. R. A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J. Biomol. Screen 4, 67–73 (1999).
McNamara, C. W. et al. Targeting Plasmodium PI(4)K to eliminate malaria. Nature 504, 248–253 (2013).
García-Domínguez, P., Dell’aversana, C., Alvarez, R., Altucci, L. & de Lera, A. R. Synthetic approaches to DNMT inhibitor SGI-1027 and effects on the U937 leukemia cell line. Bioorg. Med Chem. Lett. 23, 1631–1635 (2013).
Datta, J. et al. A new class of quinoline-based DNA hypomethylating agents reactivates tumor suppressor genes by blocking DNA methyltransferase 1 activity and inducing its degradation. Cancer Res 69, 4277–4285 (2009).
Gros, C. et al. New insights on the mechanism of quinoline-based DNA Methyltransferase inhibitors. J. Biol. Chem. 290, 6293–6302 (2015).
Halby, L. et al. Rational Design of Bisubstrate-Type Analogues as Inhibitors of DNA Methyltransferases in Cancer Cells. J. Medicinal Chem. 60, 4665–4679 (2017).
Halby, L. et al. Hijacking DNA methyltransferase transition state analogues to produce chemical scaffolds for PRMT inhibitors. Philos. Trans. R. Soc. Lond. B. Biol. Sci. 373, 20170072 (2018).
Nardella, F. et al. Procainamide-SAHA Fused Inhibitors of hHDAC6 Tackle Multidrug-Resistant Malaria Parasites. J. Med Chem. 64, 10403–10417 (2021).
Nardella, F. et al. DNA methylation bisubstrate inhibitors are fast-acting drugs active against artemisinin-resistant plasmodium falciparum parasites. ACS Cent. Sci. 6, 16–21 (2020).
Malmquist, N. A. et al. Histone methyltransferase inhibitors are orally bioavailable, fast-acting molecules with activity against different species causing malaria in humans. Antimicrob. Agents Chemother. 59, 950–959 (2015).
Malmquist, N. A., Moss, T. A., Mecheri, S., Scherf, A. & Fuchter, M. J. Small-molecule histone methyltransferase inhibitors display rapid antimalarial activity against all blood stage forms in Plasmodium falciparum. Proc. Natl Acad. Sci. USA 109, 16708–16713 (2012).
Kubicek, S. et al. Reversal of H3K9me2 by a small-molecule inhibitor for the G9a histone methyltransferase. Mol. Cell 25, 473–481 (2007).
Sun, L. et al. Synthesis and biological evaluations of 3-substituted indolin-2-ones: a novel class of tyrosine kinase inhibitors that exhibit selectivity toward particular receptor tyrosine kinases. J. Med Chem. 41, 2588–2603 (1998).
Hallyburton, I. et al. Screening a protein kinase inhibitor library against Plasmodium falciparum. Malar. J. 16, 446 (2017).
Ventafridda, V., Martino, G., Mandelli, V. & Emanueli, A. Indoprofen, a new analgesic and anti-inflammatory drug in cancer pain. Clin. Pharm. Ther. 17, 284–289 (1975).
David, K. & De Jongh, S. E. Some biological properties of equilin. Biochem J. 29, 371–377 (1935).
Beall, D. Some notes on the isolation of oestrone and equilin from the urine of pregnant mares. Biochem J. 30, 577–581 (1936).
Agtarap, A., Chamberlin, J. W., Pinkerton, M. & Steinrauf, L. The structure of monensic acid, a new biologically active compound. J. Am. Chem. Soc. 89, 5737–5739 (1967).
Gilbert, P. & Moore, L. E. Cationic antiseptics: diversity of action under a common epithet. J. Appl Microbiol 99, 703–715 (2005).
Jimenez-Diaz, M. B. et al. Improved murine model of malaria using Plasmodium falciparum competent strains and non-myelodepleted NOD-scid IL2Rgammanull mice engrafted with human erythrocytes. Antimicrob. Agents Chemother. 53, 4533–4536 (2009).
Jimenez-Diaz, M. B. et al. (+)-SJ733, a clinical candidate for malaria that acts through ATP4 to induce rapid host-mediated clearance of Plasmodium. Proc. Natl Acad. Sci. USA 111, E5455–E5462 (2014). .
Rottmann, M. et al. Spiroindolones, a potent compound class for the treatment of malaria. Science 329, 1175–1180 (2010).
Kuhen, K. L. et al. KAF156 is an antimalarial clinical candidate with potential for use in prophylaxis, treatment, and prevention of disease transmission. Antimicrob. Agents Chemother. 58, 5060–5067 (2014).
LaMonte, G. M. et al. Pan-active imidazolopiperazine antimalarials target the Plasmodium falciparum intracellular secretory pathway. Nat. Commun. 11, 1780 (2020).
Paquet, T. et al. Antimalarial efficacy of MMV390048, an inhibitor of Plasmodium phosphatidylinositol 4-kinase. Sci. Transl. Med. 9, eaad9735 (2017).
Charman, S. A. et al. Synthetic ozonide drug candidate OZ439 offers new hope for a single-dose cure of uncomplicated malaria. Proc. Natl Acad. Sci. USA 108, 4400–4405 (2011).
van Pelt-Koops, J. C. et al. The spiroindolone drug candidate NITD609 potently inhibits gametocytogenesis and blocks Plasmodium falciparum transmission to anopheles mosquito vector. Antimicrob. Agents Chemother. 56, 3544–3548 (2012).
Yipsirimetee, A. et al. Assessment In Vitro of the Antimalarial and Transmission-Blocking Activities of Cipargamin and Ganaplacide in Artemisinin-Resistant Plasmodium falciparum. Antimicrobial Agents Chemother. 66, e01481–01421 (2022).
Dechering, K. J. et al. Modelling mosquito infection at natural parasite densities identifies drugs targeting EF2, PI4K or ATP4 as key candidates for interrupting malaria transmission. Sci. Rep. 7, 17680 (2017).
Henry, N. B. et al. Assessment of the transmission blocking activity of antimalarial compounds by membrane feeding assays using natural Plasmodium falciparum gametocyte isolates from West-Africa. PLoS One 18, e0284751 (2023).
Upton, L. M. et al. Lead clinical and preclinical antimalarial drugs can significantly reduce sporozoite transmission to vertebrate populations. Antimicrob. Agents Chemother. 59, 490–497 (2015).
Carucci, M. et al. Safe drugs with high potential to block malaria transmission revealed by a spleen-mimetic screening. Nat. Commun. 14, 1951 (2023).
D’Alessandro, S. et al. Salinomycin and other ionophores as a new class of antimalarial drugs with transmission-blocking activity. Antimicrob. Agents Chemother. 59, 5135–5144 (2015).
Gumila, C., Ancelin, M. L., Delort, A. M., Jeminet, G. & Vial, H. J. Characterization of the potent in vitro and in vivo antimalarial activities of ionophore compounds. Antimicrob. Agents Chemother. 41, 523–529 (1997).
Adovelande, J. & Schrével, J. Carboxylic ionophores in malaria chemotherapy: the effects of monensin and nigericin on Plasmodium falciparum in vitro and Plasmodium vinckei petteri in vivo. Life Sci. 59, Pl309–Pl315 (1996).
Bharti, H., Singal, A., Raza, M., Ghosh, P. C. & Nag, A. Ionophores as Potent Anti-malarials: A Miracle in the Making. Curr. Top. Med Chem. 18, 2029–2041 (2019).
Maher, S. P. et al. Probing the distinct chemosensitivity of Plasmodium vivax liver stage parasites and demonstration of 8-aminoquinoline radical cure activity in vitro. Sci. Rep. 11, 19905 (2021).
Chapman, H. D., Jeffers, T. K. & Williams, R. B. Forty years of monensin for the control of coccidiosis in poultry. Poult. Sci. 89, 1788–1801 (2010).
Antoszczak, M., Steverding, D. & Huczyński, A. Anti-parasitic activity of polyether ionophores. Eur. J. medicinal Chem. 166, 32–47 (2019).
Lavine, M. D. & Arrizabalaga, G. Analysis of monensin sensitivity in Toxoplasma gondii reveals autophagy as a mechanism for drug induced death. PLoS One 7, e42107 (2012).
Lavine, M. D. & Arrizabalaga, G. The antibiotic monensin causes cell cycle disruption of Toxoplasma gondii mediated through the DNA repair enzyme TgMSH-1. Antimicrob. Agents Chemother. 55, 745–755 (2011).
Charvat, R. A. & Arrizabalaga, G. Oxidative stress generated during monensin treatment contributes to altered Toxoplasma gondii mitochondrial function. Sci. Rep. 6, 22997 (2016).
Maron, M. I. et al. Maduramicin rapidly eliminates malaria parasites and potentiates the gametocytocidal activity of the pyrazoleamide PA21A050. Antimicrobial Agents Chemother. 60, 1492–1499 (2016).
Das, S. et al. Na+ Influx Induced by New Antimalarials Causes Rapid Alterations in the Cholesterol Content and Morphology of Plasmodium falciparum. PLoS Pathog. 12, e1005647 (2016).
Spillman, N. J. et al. Na(+) regulation in the malaria parasite Plasmodium falciparum involves the cation ATPase PfATP4 and is a target of the spiroindolone antimalarials. Cell Host Microbe 13, 227–237 (2013).
Vaidya, A. B. et al. Pyrazoleamide compounds are potent antimalarials that target Na+ homeostasis in intraerythrocytic Plasmodium falciparum. Nat. Commun. 5, 5521 (2014).
Mamouei, Z. et al. Alexidine dihydrochloride has broad-spectrum activities against diverse fungal pathogens. mSphere 3, e00539-18 (2018).
Ganendren, R. et al. In vitro antifungal activities of inhibitors of phospholipases from the fungal pathogen Cryptococcus neoformans. Antimicrob. Agents Chemother. 48, 1561–1569 (2004).
Doughty-Shenton, D. et al. Pharmacological targeting of the mitochondrial phosphatase PTPMT1. J. Pharm. Exp. Ther. 333, 584–592 (2010).
Yip, K. W. et al. Potential use of alexidine dihydrochloride as an apoptosis-promoting anticancer agent. Mol. Cancer Therapeutics 5, 2234–2240 (2006).
Bao, M. H. et al. Genome-wide CRISPR-Cas9 knockout library screening identified PTPMT1 in cardiolipin synthesis is crucial to survival in hypoxia in liver cancer. Cell Rep. 34, 108676 (2021).
Muselli, F. et al. Repurposing the bis-biguanide alexidine in combination with tyrosine kinase inhibitors to eliminate leukemic stem/progenitor cells in chronic myeloid leukemia. Cancers (Basel) 15, 995 (2023).
dos Santos, M. et al. Medicines for malaria venture pandemic box in vitro screening identifies compounds highly active against the tachyzoite stage of toxoplasma gondii. Tropical Med. Infect. Dis. 8, 510 (2023).
Jia, X. et al. Phosphatase inhibitors BVT-948 and alexidine dihydrochloride inhibit sexual development of the malaria parasite Plasmodium berghei. Int J. Parasitol. Drugs Drug Resist 19, 81–88 (2022).
Yoo, J., Choi, S. & Medina-Franco, J. L. Molecular modeling studies of the novel inhibitors of DNA methyltransferases SGI-1027 and CBC12: implications for the mechanism of inhibition of DNMTs. PLoS One 8, e62152 (2013).
Rilova, E. et al. Design, synthesis and biological evaluation of 4-amino-N- (4-aminophenyl)benzamide analogues of quinoline-based SGI-1027 as inhibitors of DNA methylation. ChemMedChem 9, 590–601 (2014).
Govindaraju, G., Jabeena, C. A., Sethumadhavan, D. V., Rajaram, N. & Rajavelu, A. DNA methyltransferase homologue TRDMT1 in Plasmodium falciparum specifically methylates endogenous aspartic acid tRNA. Biochim Biophys. Acta Gene Regul. Mech. 1860, 1047–1057 (2017).
Hammam, E. et al. Malaria parasite stress tolerance is regulated by DNMT2-Mediated tRNA cytosine methylation. mBio 12, e0255821 (2021).
Lucky, A. B. et al. Characterization of the dual role of Plasmodium falciparum DNA methyltransferase in regulating transcription and translation. Nucleic Acids Res 51, 3918–3933 (2023).
Lyko, F. The DNA methyltransferase family: a versatile toolkit for epigenetic regulation. Nat. Rev. Genet. 19, 81–92 (2018).
Dobrescu, I. et al. Plasmodium falciparum Eukaryotic Translation Initiation Factor 3 is Stabilized by Quinazoline-Quinoline Bisubstrate Inhibitors. ACS Infect. Dis. 9, 1257–1266 (2023).
Moreno-Sabater, A., Perignon, J. L., Mazier, D., Lavazec, C. & Soulard, V. Humanized mouse models infected with human Plasmodium species for antimalarial drug discovery. Expert Opin. Drug Discov. 13, 131–140 (2018).
Duffier, Y. et al. A humanized mouse model for sequestration of Plasmodium falciparum sexual stages and in vivo evaluation of gametocytidal drugs. Sci. Rep. 6, 35025 (2016).
Vale, N., Moreira, R. & Gomes, P. Primaquine revisited six decades after its discovery. Eur. J. medicinal Chem. 44, 937–953 (2009).
Dicko, A. et al. Primaquine to reduce transmission of Plasmodium falciparum malaria in Mali: a single-blind, dose-ranging, adaptive randomised phase 2 trial. Lancet Infect. Dis. 16, 674–684 (2016).
Bradley, J. et al. Transmission-blocking Effects of Primaquine and Methylene Blue Suggest Plasmodium falciparum Gametocyte Sterilization Rather Than Effects on Sex Ratio. Clin. Infect. Dis. 69, 1436–1439 (2019).
White, N. J. et al. Assessment of therapeutic responses to gametocytocidal drugs in Plasmodium falciparum malaria. Malar. J. 13, 483 (2014).
Graves, P. M., Choi, L., Gelband, H. & Garner, P. Primaquine or other 8-aminoquinolines for reducing Plasmodium falciparum transmission. Cochrane Database Syst. Rev. 2, Cd008152 (2018).
McCarthy, J. S. et al. A phase 1, placebo-controlled, randomized, single ascending dose study and a volunteer infection study to characterize the safety, pharmacokinetics, and antimalarial activity of the plasmodium phosphatidylinositol 4-kinase inhibitor MMV390048. Clin. Infect. Dis. 71, e657–e664 (2020).
Collins, K. A. et al. A controlled human malaria infection model enabling evaluation of transmission-blocking interventions. J. Clin. Invest 128, 1551–1562 (2018).
McCarthy, J. S. et al. A single-dose combination study with the experimental antimalarials artefenomel and dsm265 to determine safety and antimalarial activity against blood-stage plasmodium falciparum in healthy volunteers. Antimicrob. Agents Chemother. 64, e01371-19 (2019).
Zhang, R. et al. A basis for rapid clearance of circulating ring-stage malaria parasites by the spiroindolone KAE609. J. Infect. Dis. 213, 100–104 (2016).
Dennis, A. S. M., Lehane, A. M., Ridgway, M. C., Holleran, J. P. & Kirk K. Cell swelling induced by the antimalarial kae609 (cipargamin) and other pfatp4-associated antimalarials. Antimicrob. Agents Chemother. 62, e00087-18 (2018).
White, N. J. et al. Spiroindolone KAE609 for falciparum and vivax malaria. N. Engl. J. Med 371, 403–410 (2014).
McCarthy, J. S. et al. Defining the Antimalarial Activity of Cipargamin in Healthy Volunteers Experimentally Infected with Blood-Stage Plasmodium falciparum. Antimicrob. Agents Chemother. 65, e01423-20 (2021).
Schmitt, E. K. et al. Efficacy of Cipargamin (KAE609) in a Randomized, Phase II Dose-Escalation Study in Adults in Sub-Saharan Africa With Uncomplicated Plasmodium falciparum Malaria. Clin. Infect. Dis. 74, 1831–1839 (2021).
Hien, T. T. et al. Estimation of the in vivo mic of cipargamin in uncomplicated Plasmodium falciparum Malaria. Antimicrob. Agent. Chemother. 61, https://doi.org/10.1128/aac.01940-01916 (2017).
McCarthy, J. S. et al. A pilot randomised trial of induced blood-stage Plasmodium falciparum infections in healthy volunteers for testing efficacy of new antimalarial drugs. PLoS One 6, e21914 (2011).
Pasay, C. J. et al. Piperaquine monotherapy of drug-susceptible plasmodium falciparum infection results in rapid clearance of parasitemia but is followed by the appearance of gametocytemia. J. Infect. Dis. 214, 105–113 (2016).
Farid, R., Dixon, M. W., Tilley, L. & McCarthy, J. S. Initiation of gametocytogenesis at very low parasite density in Plasmodium falciparum infection. J. Infect. Dis. 215, 1167–1174 (2017).
Alkema, M. et al. A randomized clinical trial to compare plasmodium falciparum gametocytemia and infectivity after blood-stage or mosquito bite-induced controlled malaria infection. J. Infect. Dis. 224, 1257–1265 (2021).
Webster, R. et al. Transmission blocking activity of low-dose tafenoquine in healthy volunteers experimentally infected with plasmodium falciparum. Clin. Infect. Dis. 76, 506–512 (2023).
White, N. J. Pharmacokinetic and pharmacodynamic considerations in antimalarial dose optimization. Antimicrob. Agents Chemother. 57, 5792–5807 (2013).
Tang, H. & Mayersohn, M. A global examination of allometric scaling for predicting human drug clearance and the prediction of large vertical allometry. J. Pharm. Sci. 95, 1783–1799 (2006).
Lambros, C. & Vanderberg, J. P. Synchronization of Plasmodium falciparum erythrocytic stages in culture. J. Parasitol. 65, 418–420 (1979).
Labun, K., Montague, T. G., Gagnon, J. A., Thyme, S. B. & Valen, E. CHOPCHOP v2: a web tool for the next generation of CRISPR genome engineering. Nucleic Acids Res 44, W272–W276 (2016).
Gibson, D. G. et al. HO. Enzymatic assembly of DNA molecules up to several hundred kilobases. Nat. Methods 6, 343–345 (2009).
Birnbaum, J. et al. A genetic system to study Plasmodium falciparum protein function. Nat. Methods 14, 450–456 (2017).
Thomas, J. A. et al. Development and application of a simple plaque assay for the human malaria parasite plasmodium falciparum. PLoS ONE 11, e0157873 (2016).
Brancucci, N. M. B. et al. Lysophosphatidylcholine regulates sexual stage differentiation in the human malaria parasite plasmodium falciparum. Cell 171, 1532–1544 e1515 (2017).
Bon, C. et al. Synthesis and biological activity of a cytostatic inhibitor of MLLr leukemia targeting the DOT1L protein. Molecules 26, 5300 (2021).
Pechalrieu, D. et al. Bisubstrate-type chemical probes identify GRP94 as a potential target of cytosine-containing adenosine analogs. ACS Chem. Biol. 15, 952–961 (2020).
Auld, D. S. et al. A basis for reduced chemical library inhibition of firefly luciferase obtained from directed evolution. J. Med Chem. 52, 1450–1458 (2009).
Snyder, C., Chollet, J., Santo-Tomas, J., Scheurer, C. & Wittlin, S. In vitro and in vivo interaction of synthetic peroxide RBx11160 (OZ277) with piperaquine in Plasmodium models. Exp. Parasitol. 115, 296–300 (2007).
